Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study.

Abstract

603 Background: T-DM1 is approved for HER2-positive metastatic breast cancer (MBC). A pooled analysis of T-DM1 trials (N = 884) suggested a higher rate of grade ≥ 3 adverse events (AEs) in patients...